Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Dr Hui Xiao,regeneron,United States

Dr. Hui Xiao šŸ§ŖšŸ”¬ is a distinguished scientist specializing in biochemistry, structural biology, and mass spectrometry. With a strong focus on microtubule dynamics, protein interactions, and drug mechanisms, he has made significant contributions to understanding cellular processes. As a co-first author and lead researcher, his work has been published in esteemed journals like J. Mol. Biol., Biochemistry, and J. Biol. Chem.. His expertise spans hydrogen-deuterium exchange, proteomics, and molecular stabilization studies. Dr. Xiao’s research has advanced drug discovery, particularly in cancer therapeutics and protein biochemistry. šŸ“ššŸ” His innovative approaches continue to impact biomedical sciences globally. šŸŒāœØ

Publication Profile

Scopus

Education

Dr. Hui Xiao šŸŽ“ holds a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst (2005) and a degree in Applied Chemistry from Peking University, China (1992). Currently serving as an Associate Director at Regeneron Pharmaceuticals šŸ¢, he specializes in protein characterization using mass spectrometry. With over a decade at Regeneron, he has progressed through roles as a Senior Staff Scientist and Staff Scientist. Previously, he held academic positions at Albert Einstein College of Medicine 🧬, advancing from Instructor to Research Associate Professor. His expertise spans analytical chemistry, protein analysis, and therapeutic protein research, making significant contributions to biomedical science. šŸ”¬

Professional Impact

Dr. Hui Xiao šŸŽ“ is a distinguished scientist with over 20 years of experience in academia and the biotechnology industry. Currently, he serves as an Associate Director of Analytical Chemistry at Regeneron Pharmaceuticals šŸ¢, a leading biotech company. His expertise lies in mass spectrometry applications for protein characterization šŸ”¬, contributing to advancements in therapeutic development. Before joining Regeneron, Dr. Xiao held esteemed faculty positions at Albert Einstein College of Medicine 🧬, progressing from Instructor to Research Associate Professor. His extensive research and leadership have played a crucial role in bridging analytical chemistry with biopharmaceutical innovation, impacting drug discovery and development. šŸš€

Scientific Contributions

Dr. Hui Xiao šŸŽ“ is a leading expert in protein-ligand interactions, structural proteomics, and therapeutic protein analysis šŸ”¬. His pioneering work includes the application of hydrogen-deuterium exchange mass spectrometry (HDX-MS) for epitope mapping 🧩 and microtubule stabilization research. With a deep focus on drug characterization and regulatory sciences, his contributions have significantly advanced biopharmaceutical development šŸ’Š. His expertise in mass spectrometry-driven protein analysis has helped enhance the understanding of molecular mechanisms, improving therapeutic strategies. Through innovation and research, Dr. Xiao continues to play a vital role in shaping the future of biopharmaceutical science and drug discovery. šŸš€

Potential Considerations

Dr. Hui Xiao šŸŽ“ is a renowned expert in analytical and protein chemistry, with groundbreaking work in epitope mapping and protein characterization šŸ”¬. While his contributions significantly impact drug development, the Pharmaceutical Innovation Achievement Award šŸ† may prioritize direct advancements in drug discovery and novel pharmaceutical interventions šŸ’Š. His research has important regulatory and therapeutic implications, but highlighting specific drug innovations or regulatory breakthroughs he has led would further strengthen his case. By showcasing his role in pioneering pharmaceutical advancements, Dr. Xiao’s influence in shaping modern biopharmaceutical science can be fully recognized and appreciated. šŸš€

Research Focus

Dr. Hui Xiao’s research primarily focuses on analytical chemistry 🧪, particularly in the quantitative analysis of biomolecules 🧬 using advanced mass spectrometry techniques āš–ļø. His work involves CRISPR sgRNA modification analysis šŸ§¬šŸ”¬ and the development of LC-MS-based assays for biological therapeutics šŸ’Š. He specializes in phosphorothioate isomer detection šŸ”„ and liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) šŸ“Š for precise biomolecular quantification. His contributions are crucial in drug discovery šŸ„, gene editing 🧬, and biopharmaceutical development šŸ’‰. His expertise bridges biotechnology šŸ”¬ and analytical methodologies šŸ“ˆ, advancing innovations in therapeutic monitoring and molecular diagnostics šŸ„.

Publication Top Notes

Quantitative Analysis of Phosphorothioate Isomers in CRISPR sgRNA at Single-Residue Resolution Using Endonuclease Digestion Coupled with Liquid Chromatography Cyclic Ion Mobility Mass Spectrometry (LC/cIMS)

Generic Enrichment Method for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Biological Therapeutics in Serum

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Dr Ayaz Ahmed, ICCBS – University of Karachi, Pakistan

Dr. Ayaz Ahmed šŸ§¬šŸ”¬ is a Principal Investigator and Assistant Professor at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), ICCBS, University of Karachi, Pakistan. With a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China, and an M.Sc. in Microbiology from the University of Karachi, his research focuses on microbial profiling, anti-biofilm agents, and infectious disease models. Dr. Ahmed has supervised numerous postgraduate students and received multiple international awards, including recognition from the American Society for Microbiology and Bill & Melinda Gates Foundation. He also leads funded projects on combating antibiotic-resistant pathogens. 🌟

Publication Profile

google scholar

Qualifications

Dr. Ayaz Ahmed holds a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China (2012), and a Master’s in Microbiology from the University of Karachi, Pakistan (2006, First Division). šŸ§¬šŸŽ“ His doctoral research focused on the “Microbial profiling of dental plaque/Biofilm from dental caries and periodontitis patients” and explored the effects of Lactobacillus species on S. mutans biofilm formation. šŸ¦·šŸ”¬ With a strong academic foundation and research expertise in microbiology and molecular biology, Dr. Ayaz contributes significantly to the understanding of microbial interactions in dental health and disease. 🌟

Job Responsibilities

Dr. Ayaz Ahmed is a Principal Investigator at the Cell Biology Lab, where he oversees the Imaging Facility, maintaining high-end fluorescence and light microscopes. He supports students by assisting them in acquiring high-quality images for their theses and manuscripts. Dr. Ahmed also manages the National Animal Facility for Laboratory Animal Research and Care. He supervises routine animal house operations and collaborates with a veterinary doctor to maintain SPF rats, mice, and hamsters. He is responsible for establishing models for infectious diseases and memory deficits to evaluate the efficacy of natural compounds. Dr. Ahmed also conducts toxicological studies and trains students in ethical animal research practices. šŸ§¬šŸ”¬šŸ

Student Supervised

Dr. Ayaz Ahmed and his team of dedicated researchers have made significant strides in their exploration of innovative therapeutic strategies. Among the Ph.D. candidates, Zulfiqar Ahmed’s research on controlling salmonellosis through probiotics in poultry, Binte Zehra’s study on modulating the metastatic potential of NSCLC, and Jazib Shafiq’s investigation into gut dysbiosis and anxiety have all been awarded. Additionally, Afshan Shams, Yamina Usmani, and Shariqa Khuwaja are examining the potential of natural and synthetic compounds in combating oral cancer and other diseases. Several M. Phil. students are also contributing to research on antimicrobial resistance and cancer therapies. šŸ§ŖšŸ”¬šŸ§«

Honors and Awards

Dr. Ayaz Ahmed has earned numerous accolades throughout his distinguished career. In 2024, he received the Award for Collaborative Scientific Achievement from the Institute of Food Science and Technology, Chinese Academy of Agriculture Science, Beijing. He also became an International Federation for Biosafety Association (IFBA) Certified Biological Waste Management Professional and Bio-risk Management Professional in 2023. Dr. Ahmed was selected as a Mentor for the ASM Future Leaders Mentoring Fellowship Program in 2023 and was awarded the Health Security Partner Grant by the Bill & Melinda Gates Foundation in 2021. He has also earned prestigious travel awards and fellowships, including the American Society for Microbiology ID Fellowship and the Science and Technology Talent Award. šŸ…šŸŒšŸ¦ 

Completed Projects

Dr. Ayaz Ahmed has led multiple impactful research projects focused on combating multidrug-resistant microorganisms and improving public health. His research on the effect of synthetic and natural compounds on biofilm formation was funded by the Higher Education Commission of Pakistan (HEC) under project # HEC No: PD-IPFP/HRD/HEC/ 2013/1182. He also contributed to projects such as Personal Protective Equipment for Sindh Poultry Vaccine Center (funded by CRDF Global, USA), and oral pathogens related to dental caries (funded by ICCBS). Notably, his work on antimicrobial-resistant water contaminants, funded by the U.S.-Pakistan Centers for Advanced Studies in Water, aims to improve water quality. He further advanced research on antimicrobial and antibiofilm agents targeting Acinetobacter baumannii and Klebsiella pneumonia with funding from HEC. šŸ’§šŸ”¬šŸ¦ 

Professional Experience

Dr. Ayaz Ahmed has had a distinguished career in academia and research. Since June 2017, he has been serving as an Assistant Professor at the International Center for Chemical and Biological Sciences, University of Karachi. Prior to this, he worked as a Senior Research Officer at the same institution from November 2013 to June 2017. Dr. Ahmed also pursued Post-Doctoral training in Behavioral Sciences at Hunan Drug Safety Evaluation in Changsha, China, from January 2016 to February 2017. His earlier roles include Assistant Professor on Interim Placement, Research Officer in Avian Influenza Vaccine Production, and a research intern in the National Internship Program. šŸ§ŖšŸ“š

Professional Membership

Dr. Ayaz Ahmed is an active member of several prestigious professional organizations, contributing significantly to the fields of microbiology and infectious diseases. His memberships include the American Society for Microbiology (ASM) 🦠, the Pakistan Biological Safety Association (PBSA) 🧫, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) šŸŒ. Additionally, he is a member of the American Association of Cancer Research (AACR) šŸŽ—ļø and the Medical Microbiology & Infectious Disease Society of Pakistan (MMIDSP) šŸ‡µšŸ‡°. These memberships reflect his commitment to advancing research and innovation in microbiology, infectious diseases, and cancer research.

Research Focus

Dr. Ayaz Ayaz Ahmed research focus primarily revolves around microbiology, particularly in the fields of gut microbiota analysis, antimicrobial resistance, and biofilm formation. His studies often investigate the interactions between microorganisms and the human or animal host, such as comparing gut microbe profiles between healthy individuals and those with conditions like hyperthyroidism and liver cirrhosis. Additionally, Dr. Ahmed explores innovative therapeutic approaches, including the development of antimicrobial agents, such as nanoparticles conjugated with antibiotics to combat biofilm-forming pathogens like Klebsiella pneumoniae and Staphylococcus aureus. His work has significant implications for medical microbiology and the treatment of infectious diseases. šŸ¦ šŸ”¬

Publication Top Notes

Gut microbe analysis between hyperthyroid and healthy individuals

Phylogenetic and biological characterization of Newcastle disease virus isolates from Pakistan

Biofilm inhibitory effect of chlorhexidine conjugated gold nanoparticles against Klebsiella pneumoniae

Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals

Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae

Effect of Lactobacillus species on Streptococcus mutans biofilm formation.

Comparison of oral microbiota in orthodontic patients and healthy individuals

Synthesis and Chemosensing of Nitrofurazone using Olive oil based Silver Nanoparticles (O-AgNPs)

Isolation of dihydrobenzofuran derivatives from ethnomedicinal speciesĀ Polygonum barbatumĀ as anticancer compounds

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. šŸŒšŸ’ŠšŸ”¬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. šŸ§ šŸ“ššŸŽ“

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at MƤlardalen University in 1981. šŸ§‘ā€šŸ”¬šŸ’‰šŸ“š

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. šŸŒšŸ”¬šŸ§ 

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. šŸ§ šŸ’Š

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. šŸ§ šŸ“ššŸ’Š

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at UmeĆ„ University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. šŸŽ“šŸ§ šŸ’”

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. šŸ§ šŸ’ŠšŸŽ“

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. šŸ§ šŸ”¬šŸ’Š His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Prof. Rasha Azzam|Drug Discovery and Development|Best Researcher Award

Prof. Rasha Azzam|Drug Discovery and Development |Best Researcher Award

Prof. Rasha Azzam at Helwan University,Egypt

PROFILEĀ Ā 

orcid

Early Academic Pursuits šŸŽ“

Prof. Rasha A. Azzam’s academic journey began with her outstanding performance in chemistry at Helwan University, Egypt, where she graduated with a Bachelor of Science (B.Sc.) in Chemistry in 1993. Her excellence in academia was recognized early on, as she graduated with class honors and was placed on the Dean’s List. Driven by her passion for organic chemistry, she pursued a Master of Science (M.Sc.) degree in Organic Chemistry at Helwan University, completing it in 1996. Her academic curiosity and dedication led her to further her studies internationally, earning a prestigious Ph.D. in Organic Chemistry in 2003 from the Catholic University of Leuven in Belgium. Her diverse educational background laid the foundation for a career defined by groundbreaking research and academic excellence.

Professional Endeavors šŸ§‘ā€šŸ”¬

Prof. Azzam’s professional career spans over two decades of teaching, research, and leadership in various prestigious academic institutions across the globe. She is currently a Professor of Organic Chemistry at the Faculty of Science, Helwan University, where she has been contributing since 2021. Prior to this, she held the position of Associate Professor of Organic Chemistry at the same institution from 2016 to 2021, demonstrating her upward trajectory in academia.

Her teaching and research influence extended beyond Egypt. She has held positions as an Associate Professor at Taibah University in Saudi Arabia, Nigerian Turkish Nile University in Nigeria, and the American University in Nigeria, where she was a co-founder of the Petroleum Chemistry Program. Additionally, she has served as a Visiting Professor at Virginia Commonwealth University in 2024, further showcasing her international academic reach.

Contributions and Research Focus šŸ”¬

Prof. Azzam’s research focuses on organic and medicinal chemistry, with a particular emphasis on green synthesis, nanomaterials, and antiviral agents. One of her key research interests is the development of new methods for synthesizing compounds with potential anticancer and antimicrobial properties. Her recent project, “Synthesis of new sulfa derivatives under ultrasonic irradiation as potential anticancer/antimicrobial agents,” funded by Helwan University in 2021, highlights her innovative approach to organic synthesis.

Prof. Azzam’s work also explores environmentally friendly technologies, as demonstrated by her research on “green technology based on nanoporous biodegradable polymeric membranes” for wastewater treatment, funded by the Academy of Scientific Research Technology (ASRT). She has also conducted pioneering work on nanomaterials and their applications in industrial processes, such as her research on thermoplastic elastomers based on petrochemicals and the development of anti-COVID-19 agents incorporated into nanofibrous mats.

Her research output is extensive, and she has presented several projects on global platforms, including her work on antiviral therapeutic agents and nanomaterials. Her research contributions are shaping the future of organic chemistry, particularly in the domains of green chemistry and medical applications.

Accolades and Recognition šŸ†

Prof. Azzam’s excellence in research and community service has been recognized through numerous awards and honors. In 2023, she received the prestigious Prince Mohammed Bin Fahd Scientific Award for her contributions to scientific production that serves community development within the framework of sustainable development goals. In the same year, she was honored with Helwan University’s Outstanding Scientific Achievement Award in Basic and Applied Sciences.

She has also been recognized for her mentoring and supervision of students, receiving Best Master Thesis Awards for two of her master’s students, Rasha Essam (2020) and Heba Elboshi (2023). Her commitment to advancing research was further acknowledged when she received the Research Excellence Awards for her students, Rokia Ramadan (2019) and Rasha Essam (2020). Additionally, Prof. Azzam was awarded a Silver Medal from the Academy of Scientific Research Technology (ASRT) in 2018 for her outstanding contributions to science.

Her impact extends internationally, with her receiving the Outstanding Faculty Member Award from the American University in Nigeria in 2007, and a research scholarship from the Catholic University of Leuven in 2001.

Impact and Influence šŸŒ

Prof. Azzam’s influence is felt not only through her research but also through her active participation in the scientific community. She serves as a Review Editor for Organic Chemistry on the Editorial Board of Frontiers in Chemistry and as an editor for the Journal of Chemistry and The Scientific World Journal, both published by Hindawi. She is also a grant evaluator for the Fulbright Binational Scholarship Program, where she helps assess the next generation of academic leaders.

Her commitment to education and community service is reflected in her involvement in organizing training workshops for high school teachers and instructing lab sessions for the AUN Community School. Prof. Azzam is also a member of the Egyptian Society for Basic Sciences, where she contributes to the development of the scientific community in Egypt.

Legacy and Future Contributions 🌟

Prof. Rasha A. Azzam’s legacy is built on her unwavering dedication to advancing organic chemistry, fostering academic excellence, and mentoring the next generation of scientists. Her research has laid the groundwork for significant developments in green chemistry, nanomaterials, and medicinal chemistry. With her continued focus on innovative solutions for pressing global challenges, such as wastewater treatment and the development of antiviral agents, she is poised to make even more impactful contributions in the years to come.

šŸŽ“PublicationĀ 

In the pursuit of novel therapeutic agents: synthesis, anticancer evaluation, and physicochemical insights of novel pyrimidine-based 2-aminobenzothiazole derivatives

  • AuthorsĀ  Ā :Toka I. Ismail; Nashwa El-Khazragy; Rasha A. Azzam
  • JournalĀ  Ā  :RSC Advances
  • YearĀ  Ā  Ā  Ā  Ā :2024

Novel High-Performance Functionalized and Grafted Bio-Based Chitosan Adsorbents for the Efficient and Selective Removal of Toxic Heavy Metals from Contaminated Water

  • AuthorsĀ  Ā :Mohammad Monir;Ā Rasha E. Elsayed;Ā Rasha Azzam;Ā Tarek M. Madkour
  • JournalĀ  Ā  :Polymers
  • YearĀ  Ā  Ā  Ā  Ā :2024

Crystal structure of 4-(benzo[d]thiazol-2-yl)-1,2-dimethyl-1H-pyrazol-3(2H)-one

  • AuthorsĀ  Ā :Heba A. Elboshi;Ā Rasha A. Azzam;Ā Galal H. Elgemeie;Ā Peter G. Jones
  • JournalĀ  Ā  :Acta Crystallographica Section E Crystallographic Communications
  • YearĀ  Ā  Ā  Ā  Ā :2024

Synthesis of New Guanidine Benzothiazole Derivative and Its Application as Eco-Friendly Corrosion Inhibitor

  • AuthorsĀ  Ā :Ā Abdel-karim, Amal M.;Ā Azzam, Rasha A.;Ā Shehata, Omnia S.;Ā Adly, Mohamed A.;Ā El-Shamy, Omnia A. A.;Ā El-Mahdy, Gamal A.
  • JournalĀ  Ā  :Chemistry
  • YearĀ  Ā  Ā  Ā  Ā :2023

Crystal structure of 2-{[5-(methylsulfanyl)-4-phenyl-4H-1,2,4-triazol-3-yl]methyl}benzo[d]thiazole

  • AuthorsĀ  Ā : Rasha A. Azzam;Ā Galal H. Elgemeie;Ā Heba A. Elboshi;Ā Peter G. Jones
  • JournalĀ  Ā  :Crystallographica Section E Crystallographic Communications
  • YearĀ  Ā  Ā  Ā  Ā :2023